loading page

Novel therapeutic approaches to target neurodegeneration
  • +3
  • Alerie Guzman de la Fuente,
  • Silvia Pelucchi,
  • Jerome Mertens,
  • Mónica Di Luca,
  • Daniela Mauceri,
  • Elena Marcello
Alerie Guzman de la Fuente
Instituto de Investigación Sanitaria y Biomédica de Alicante
Author Profile
Silvia Pelucchi
Leopold Franzens Universität für Innsbruck
Author Profile
Jerome Mertens
Leopold Franzens Universität für Innsbruck
Author Profile
Mónica Di Luca
Università degli Studi di Milano
Author Profile
Daniela Mauceri
University of Marburg
Author Profile
Elena Marcello
Università degli Studi di Milano

Corresponding Author:[email protected]

Author Profile


Ageing is the main risk factor common to most primary neurodegenerative disorders. Indeed, age-related brain alterations have been long considered to predispose to neurodegeneration. Although protein misfolding and the accumulation of toxic protein aggregates have been contemplated as causative events in neurodegeneration, several biological pathways affected by brain ageing are also contributing to pathogenesis. Here, we discuss the evidence showing the involvement of the mechanisms controlling neuronal structure, gene expression, autophagy, cell metabolism, and neuroinflammation in the onset and progression of neurodegenerative disorders. Furthermore, we review the therapeutic strategies currently under development or as future approaches designed to normalize these pathways, which may then boost brain resilience to cope with toxic protein species. Therefore, in addition to therapies targeting the insoluble protein aggregates specifically associated with each neurodegenerative disorder, these novel pharmacological approaches may be part of combined therapies designed to rescue brain function.
21 Dec 2022Submitted to British Journal of Pharmacology
21 Dec 2022Submission Checks Completed
21 Dec 2022Assigned to Editor
22 Dec 2022Reviewer(s) Assigned
24 Jan 2023Review(s) Completed, Editorial Evaluation Pending
25 Jan 2023Editorial Decision: Revise Minor
26 Feb 20231st Revision Received
27 Feb 2023Submission Checks Completed
27 Feb 2023Assigned to Editor
08 Mar 2023Reviewer(s) Assigned
15 Mar 2023Review(s) Completed, Editorial Evaluation Pending
17 Mar 2023Editorial Decision: Accept